Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-Low-Expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-Arm, Non-Randomized, Single-Center, Open Label Trial. This evidence concerns the gene ERBB2 and breast carcinoma.